The document summarizes results from the CORD Pharmacare Survey conducted from June to September 2018. It shows responses from 136 non-rare and rare disease patients about their experiences accessing drugs under their current drug plans. Most non-rare and rare disease patients reported challenges accessing needed medications due to cost or had concerns about not being able to access new drugs. The document also summarizes responses on models for a national pharmacare program and setting Canadian drug prices.

1. CORD Pharmacare Survey
June – September 2018

2. Experience with Current Drug Plan -
NonRare & Rare Disease Patients
With Current Drug Plan my family
has …
Agree
strongly
Agree
somewhat
Neither
agree nor
disagree
Disagree
somewhat
Disagree
strongly
NONRARE Challenges to accessing
needed medicines
40% 21% 15% 13% 10%
RARE Challenges to accessing
needed medicines
66% 12% 1% 3% 18%
NONRARE Been denied
access to necessary drugs due
to cost
30% 15% 17% 9% 28%
RARE Been denied access to
necessary drugs due to cost
51% 7% 12% 4% 25%
NONRARE Concerns about not
accessing new drugs available
elsewhere
66% 23% 9% 0% 2%
RARE Concerns about not
accessing new drugs available
elsewhere
78% 10% 6% 1% 4%
n = 136

3. Current Drug Coverage - All
My family has … Yes No Not Sure
Employer-provided drug plan 70% 30% 1%
Personally paid for private drug plan 35% 65% 1%
Public drug coverage 58% 39% 3%
Very high drug costs covered by
public plan
45% 50% 4%
Been denied drug not on plan's list 55% 37% 8%
Experienced long delays and barriers
to access needed drugs
57% 39% 4%
Been unable to access needed drugs
due to cost or co-pay
41% 54% 5%

4. Current Drug Coverage –
(NonRare & Rare Disease Patients)
My family has … Yes No Not Sure
NONRARE Very high drug costs
covered by public plan
32% 66% 2%
RARE Very high drug costs covered
by public plan
57% 38% 4%
NONRARE Been denied drug not on
plan's list
45% 47% 8%
RARE Been denied drug not on plan's
list
64% 28% 7%
NONRARE Experienced long delays
and barriers to access needed drugs
43% 59% 0%
RARE Experienced long delays and
barriers to access needed drugs
70% 24% 6%

5. Model of Drug Programs - All
35%
25%
37%
24%
23%
19%
20%
21%
19%
10%
18%
8%
15%
14%
17%
Public or Private Choice
1st Private Mandatory
1st Public-Tax Increase
1st Payer – Private or Public
Agree Strongly Agree Somewhat Neither Disagree Somewhat Disagree Strongly

6. Model of Drug Programs
- (NonRare & Rare Disease Patients)
42%
38%
24%
30%
44%
30%
21%
23%
23%
26%
21%
36%
15%
13%
22%
15%
15%
6%
9%
11%
16%
19%
12%
13%
12%
15%
15%
9%
12%
15%
RARE Public or Private Choice
NON Public or Private Choice
RARE 1st Private Mandatory
NON 1st Private Mandatory
RARE 1st Public-Tax Increase
NON 1st Public-Tax Increase
1st Payer – Private or Public
Agree Strongly Agree Somewhat Neither Disagree Somewhat Disagree Strongly

7. Access Innovative Therapies - All
6%
73%
79%
85%
28%
15%
13%
13%
4%
6%
4%
1%
3%
6%
3%
1%
1%
0%
1%
0%
New drugs limited until more evidence
If Terminal - right to try unapproved
Clinicians immed. access new drugs
Potential benefit - monitored access
Patients should have access …
Agree Strongly Agree Some Neutral Disagree Some Agree Strongly2

8. Access to Drug Coverage - All
48%
53%
62%
79%
90%
19%
24%
20%
16%
10%
17%
14%
6%
2%
10%
4%
5%
1%
0%
6%
5%
8%
2%
0%
Supplemental private coverage
Mandatory drug coverage
Provincial additional coverage
Same essential drug list
Public catastrophic coverage
All patients should have access to …
Agree Strongly Agree Some Neutral Disagree Some Disagree Strongly

9. How Should Canada Set Drug Prices? -
All
Canadian Price should …
Agree
strongly
Agree
somewhat
Neither agree
nor disagree
Disagree
somewhat
Disagree
strongly
Promote competition with multiple
suppliers of similar products
70% 20% 8% 1% 0%
Allow Public & Private same price 69% 17% 6% 5% 4%
Include value-added supports and
benefits in pricing
60% 28% 9% 1% 2%
Include societal benefits 52% 24% 12% 4% 8%
Encourage early entry of new
drugs
48% 31% 14% 3% 4%
Reflect economic costs and
benefits
46% 25% 15% 7% 6%
Be at same price as similar GDP
countries
46% 38% 10% 3% 3%
Reflect health outcomes 45% 23% 14% 9% 9%
Recognize global price reflects
country’s GDP
24% 30% 27% 11% 8%